The EU Commission sends a Statement of Objections to the developer of a multiple sclerosis medication over misuse of the patent system and disparagement of a rival (Teva)

Antitrust: Commission sends Statement of Objections to Teva over misuse of the patent system and disparagement of rival multiple sclerosis medicine* The European Commission has informed Teva of its preliminary view that the company has breached EU antitrust rules by engaging in practices intended to delay competition to its blockbuster medicine, Copaxone. These consisted in artificially extending patent protection of Copaxone and by systematically spreading misleading information about a competing product with a view to hinder its market entry and uptake. Executive Vice-President Margrethe Vestager, in charge of competition policy, said: "Until today, there is not yet a treatment for the chronic illness of multiple sclerosis. So innovative medicines can make a major difference to

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • European Commission - DG COMP (Brussels)

Quotation

European Commission, The EU Commission sends a Statement of Objections to the developer of a multiple sclerosis medication over misuse of the patent system and disparagement of a rival (Teva), 10 October 2022, e-Competitions October 2022, Art. N° 109116

Visites 108

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues